PepGen Inc - רווח נקי למניה אחת בשנים עשר החודשים האחרונים PEPG

PepGen Inc. (PEPG) specializes in developing genetic medicines to treat muscle pathologies through scientific alliances with medical centers. This EPS (TTM) chart captures the metric at 62.50. The company is currently deploying capital toward research and development without generating commercial sales. Meanwhile, the business remains shielded from macroeconomic shocks, as the demand for biotechnology remains constant even during deep recessions.
PEPG (PepGen Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

PepGen Inc. focuses on developing RNA delivery platforms and expanding its clinical trial management staff, which requires significant capital expenditures. Analyzing the historical YoY ttm net income per share growth rate allows for an assessment of annual profit dynamics, helping investors detect a fading trend in time and avoid purchasing overvalued assets ahead of a potential correction.